Silence Therapeutics Reports Steep Revenue Decline, Doubled Net Loss, and AstraZeneca Drops SLN312 Program
SLN has more than doubled off its 52-week low of $1.97.
Summary
Silence Therapeutics announced significantly worse financial results for 2025, including a near-total collapse in collaboration revenue and a doubled net loss, alongside the termination of AstraZeneca's development of SLN312.
Key Events · Financing and Capital Events · SLN
-
Steep Revenue Decline
Collaboration revenue fell dramatically from $43.3 million in 2024 to $0.6 million for the full year ended December 31, 2025.
-
Net Loss Doubled
The company's net loss increased to $88.6 million for 2025, nearly doubling from $45.3 million in 2024.
-
AstraZeneca Terminates SLN312 Development
AstraZeneca notified Silence Therapeutics that it will not pursue further development of SLN312 beyond Phase 1, returning exclusive global rights to Silence.
-
Cash Position Decreased
Cash, cash equivalents, and short-term investments declined to $85.1 million as of December 31, 2025, from approximately $147.3 million in 2024.
Analysis · SLN · Life Sciences
Silence Therapeutics' financial health has deteriorated significantly, with collaboration revenue plummeting and net losses nearly doubling year-over-year. This indicates a substantial cash burn and raises concerns about future funding and operational runway. The decision by AstraZeneca to cease development of SLN312 is a major setback for Silence's pipeline, as it loses a key partner for a clinical asset. While the accelerated timeline for Divesiran's Phase 2 results is a positive, it is heavily overshadowed by the severe financial performance and the loss of a significant partnership. Investors should monitor the company's cash runway and its strategy for SLN312 and other pipeline assets.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLN was trading at $5.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273M. The 52-week trading range was $1.97 to $7.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.